相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
Michel R. Langlois et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease
Edward K. Duran et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease A Prespecified Secondary Analysis of the ACCELERATE Trial
Rishi Puri et al.
JAMA CARDIOLOGY (2020)
Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study
Mie Balling et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander et al.
EUROPEAN HEART JOURNAL (2019)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals
Mie Balling et al.
ATHEROSCLEROSIS (2019)
LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study
Guenther Silbernagel et al.
ATHEROSCLEROSIS (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
HEART UK consensus statement on Lipoprotein(a): A call to action
Jaimini Cegla et al.
ATHEROSCLEROSIS (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inflammatory and Cholesterol Risk in the FOURIER Trial
Erin A. Bohula et al.
CIRCULATION (2018)
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Michel R. Langlois et al.
CLINICAL CHEMISTRY (2018)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease
Anum Saeed et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker et al.
LANCET (2018)
Advances in lipid-lowering therapy through gene-silencing technologies
Borge G. Nordestgaard et al.
NATURE REVIEWS CARDIOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Development of a Novel Homogeneous Assay for Remnant Lipoprotein Particle Cholesterol
Yuhko Hirao et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2018)
Development and Population Results of a Fully Automated Homogeneous Assay for LDL Triglyceride
Yasuki Ito et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2018)
Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease
Amit V. Khera et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Nathan O. Stitziel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2016)
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial
John J. Albers et al.
ATHEROSCLEROSIS (2016)
Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-3) study
Joshua R. Lupton et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies
Parag H. Joshi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial
Sagar B. Dugani et al.
JAMA CARDIOLOGY (2016)
Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT
Erin A. Bohula et al.
CIRCULATION (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease The Atherosclerosis Risk in Communities ( ARIC) Study
Ron C. Hoogeveen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease
Paul T. Williams et al.
ATHEROSCLEROSIS (2014)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Pia R. Kamstrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Gene-Based Sequencing Identifies Lipid-Influencing Variants with Ethnicity-Specific Effects in African Americans
Amy R. Bentley et al.
PLOS GENETICS (2014)
Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
Anette Varbo et al.
CIRCULATION (2013)
High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy
Wolfgang Koenig
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile
Seth S. Martin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications
Seth S. Martin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
Pia R. Kamstrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Anette Varbo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Common variants associated with plasma triglycerides and risk for coronary artery disease
Ron Do et al.
NATURE GENETICS (2013)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Daniel I. Swerdlow et al.
LANCET (2012)
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data
Frances Wensley et al.
BRITISH MEDICAL JOURNAL (2011)
Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
Chunyu Zheng et al.
CIRCULATION (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism
Pasi Soininen et al.
ANALYST (2009)
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women
Samia Mora et al.
CIRCULATION (2009)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis
Michael P. Caulfield et al.
CLINICAL CHEMISTRY (2008)
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma
Claes Bergmark et al.
JOURNAL OF LIPID RESEARCH (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Toni I. Pollin et al.
SCIENCE (2008)
LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management
William C. Cromwell et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2007)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Borge G. Nordestgaard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease -: The Ludwigshafen Risk and Cardiovascular Health study
W März et al.
CIRCULATION (2004)
Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives
MJ Chapman
ATHEROSCLEROSIS (2003)
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet
SS Deeb et al.
JOURNAL OF LIPID RESEARCH (2003)
Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease -: The Copenhagen City Heart Study
RV Andersen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase
T Shimizugawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
